Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand

Drug and Alcohol Review

Volumn 27, Issue 6, 2008, Pages 633-639

  Wilkins, Chris ^a   Sweetsur, Paul ^a   Girling, Melissa ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

Adverse effects; Benzylpiperazine (BZP); Herbal highs; Patterns of use; Polydrug use; Population sample; Trifluoromethylphenylpiperazine (TFMPP)

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE; 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1-BENZYLPIPERAZINE; 5 HYDROXYTRYPTOPHAN; CENTRAL STIMULANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; STREET DRUG;

ADDICTION; ADOLESCENT; ADULT; ARTICLE; DRUG COMBINATION; FEMALE; HUMAN; MALE; NEW ZEALAND; SEX DIFFERENCE;

5-HYDROXYTRYPTOPHAN; ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; NEW ZEALAND; PIPERAZINES; SEROTONIN AGONISTS; SEX FACTORS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 56749174797     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230801956140     Document Type: Article

References (24)

1. Sheridan J, Butler R, Wilkins C, et al. Legal piperazinecontaining party pills - a new trend in substance misuse. Drug Alcohol Rev 2007;26:335-43.
2. Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use 2007;12: 213-25.
3. New Zealand Herald. Restraints on party pills delayed. 1 April, 2005.
4. Nicholson T. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australasia 2006;18: 180-4.
5. Baumann M, Clark R, Budzynski A, et al. Effects of 'Legal X' piperazine analogs on dopamine and serotonin release in rat brain. Ann NY Acad Sei 2004;1025:189-97.
6. McCandless D. Clubbers snap up new legal high. Guardian 13 December, 2005.
7. Kirby T. Funk pills: getting on a 'legal high'. Independent 30 May, 2006.
8. Vince G. Legally high. New Scientist 2006;191:2571:40-5.
9. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) & Europol. Europol - EMCDDA Joint report on a new psychoactive substance: 1-benzylpiperazine (BZP) (in accordance with Article 5 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances. Lisbon, 2005. Available at: http://www.emcdda.europa. eu/?nnodeid=1346 (accessed 7 March 2008).
10. European Monitoring Centre for Drugs and Drug Addiction. Risk assessment report of a new psychoactive substance: 1-benzylpiperazine (BZP) (in accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances). Lisbon, 2007. Available at: http://register.consilium.europa.eu/pdf/en/07/st10/st10458.en07.pdf (accessed 7 March 2008).
11. Bye C, Munro-Faure A, Peck A, et al. A comparison of the effects of 1-benzylpiperazine on human performance tests. Eur J Clin Pharmacol 1973;6:163-9.
12. Campbell H, Cline W, Evans M, et al. Comparison of the effects of dexamethamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1972;6:170-6.
13. Expert Advisory Committee on Drugs, The Expert Advisory Committee on Drugs (EACD). Advice to the Minister on: Benzylpiperazibe (BZP), April. EACD: Wellington, 2004.
14. Gee P, Richardson S, Woltersdorf W, et al. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. NZ Med J 2005;118:1784-94.
15. GuruGardener. Herbal highs - Party pills, undated. Available at: http://www.gurugardener.co.nz/herbal%20highs%20selection.htm (accessed 10 August 2007).
16. Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. NZ Med J 2006;119:1959-61.
17. Wilkins C, Girling M, Sweetsur P, et al. Legal party pill use in New Zealand: Prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP), June. Centre for Social and Health Outcomes Research and Evaluation (SHORE) & Te Ropu Whariki, Massey University: Auckland, 2006.
18. Hall W, Hando J. Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug Alcohol Rev 1994;13:277-84.
19. Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997;46:105-13.
20. Topp L, Hando J, Dillon P, et al. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-15.
21. TOXINZ. TOXINZ is an Internet database containing information regarding toxic compounds and the management of poisoned patients, undated. Available at: http://www.toxinz.com/ (accessed 10 August 2007).
22. Drug Enforcement Administration (DEA). Department of Justice, Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)- propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final ruling. Fed Register 2004;69:12794-7.
23. Hon Jim Anderton. BZP to be banned. 2007; 28 June 2007. Available at: http://www.progressive.org.nz/modules.php? name=News&file=article&sid= 2768 (accessed 7 March 2008).
24. Vice President Frattini. New Commission proposal to strengthen control of synthetic drug BZP 2007, 17 July 2007. Available at: http://europa.eu/rapid/ pressReleasesAction.do?reference=IP/07/1103&format=HTML&aged= 0&language=ENlguiLanguage=en (accessed 7 March 2008).